<DOC>
	<DOCNO>NCT00067730</DOCNO>
	<brief_summary>The purpose determine Drotrecogin Alfa ( activate ) affect patient blood cancer develop severe sepsis within 60 day start chemotherapy preparation bone marrow transplant ( BMT ) .</brief_summary>
	<brief_title>A Safety Evaluation Drotrecogin Alfa ( Activated ) Patients With Blood Cancer , Severe Infection Related Bone Marrow Transplantation</brief_title>
	<detailed_description>The purpose study determine Drotrecogin Alfa ( activate ) affect leukemia , lymphoma myeloma patient develop sever sepsis within 60 day start chemotherapy preparation bone marrow transplant ( BMT ) . The study evaluate safety Xigris assess risk serious bleed event , include bleed within brain serious bleed lead death .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<mesh_term>Drotrecogin alfa activate</mesh_term>
	<mesh_term>Protein C</mesh_term>
	<criteria>Participants must Leukemia , Lymphoma Myeloma . Participants must hematopoietic stem cell transplantation ( HSCT ) within past 60 day . Participants must infection either vasopressor dependent septic shock ventilatordependent respiratory failure . Participants must breathe machine require medication maintain blood pressure . Participants must increase bleeding risk due medical condition medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>